文献速递临床试验与 GCP

每周一次胰岛素icodec与每日一次德谷胰岛素在胰岛素初治2型糖尿病成人中的比较:ONWARDS 3随机临床试验

Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

该随机、双盲、非劣效、 treat-to-target、3a期试验在11个国家92个中心纳入588例胰岛素初治的2型糖尿病成人,比较每周一次icodec与每日一次德谷胰岛素。26周时icodec组HbA1c降幅优于德谷胰岛素组(估计治疗差异-0.2个百分点),体重变化无显著差异;icodec组0至26周合并2级或3级低血糖发生率显著更高(0.35 vs 0.12事件/患者年暴露;P=0.01)。

要点

  • 每周一次icodec在26周HbA1c降幅上优于每日一次德谷胰岛素(ETD -0.2个百分点)。
  • icodec与德谷胰岛素在空腹血糖变化和体重变化上无显著差异。
  • icodec组0至26周合并2级或3级低血糖发生率显著高于德谷胰岛素组。

核心结论

  • 在胰岛素初治2型糖尿病成人中,每周一次icodec治疗26周后HbA1c降幅优于每日一次德谷胰岛素,体重变化无差异,icodec组在两组均低于1事件/患者年暴露的背景下合并2级或3级低血糖事件发生率更高。

研究设计与样本

  • 随机、双盲、非劣效、treat-to-target、3a期试验,2021年3月至2022年6月在11个国家92个中心开展,纳入接受任何非胰岛素降糖药物治疗且HbA1c为7%-11%(53-97 mmol/mol)的2型糖尿病成人。
  • 共588例参与者按1:1随机分配至每周一次icodec联合每日一次安慰剂组(icodec组,n=294)或每日一次德谷胰岛素联合每周一次安慰剂组(degludec组,n=294),564例(96%)完成试验。

主要发现

  • icodec组HbA1c从基线8.6%(观察值)降至26周7.0%(估计值),degludec组从8.5%(观察值)降至7.2%(估计值),估计治疗差异-0.2(95%CI -0.3至-0.1)个百分点,证实非劣效性(P<.001)和优效性(P=.002)。
  • icodec组与degludec组在空腹血糖从基线至26周变化(ETD 0,95%CI -6至5 mg/dL;P=.90)上无显著差异。
  • icodec组与degludec组在治疗最后2周的平均每周胰岛素剂量上无显著差异。
  • 体重从基线至26周变化:icodec组2.8 kg vs degludec组2.3 kg(ETD 0.46,95%CI -0.19至1.10 kg;P=.17),无显著差异。
  • 0至31周合并2级或3级低血糖发生率:icodec组0.31 vs degludec组0.15事件/患者年暴露(P=.11),数值上icodec组更高。

关键数值与推荐

  • 主要终点为非劣效性界值0.3个百分点的HbA1c从基线至26周变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Once-weekly insulin icodec could provide a simpler dosing alternative to daily basal insulin in people with type 2 diabetes. OBJECTIVE: To evaluate the efficacy and safety of once-weekly icodec vs once-daily insulin degludec in people with insulin-naive type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-masked, noninferiority, treat-to-target, phase 3a trial conducted from March 2021 to June 2022 at 92 sites in 11 countries in adults with type 2 diabetes treated with any noninsulin glucose-lowering agents with hemoglobin A1c (HbA1c) of 7%-11% (53-97 mmol/mol). INTERVENTIONS: Participants were randomly assigned in a 1:1 ratio to receive either once-weekly icodec and once-daily placebo (icodec group; n = 294) or once-daily degludec and once-weekly placebo (degludec group; n = 294). MAIN OUTCOMES AND MEASURES: The primary end point was change in HbA1c from baseline to week 26 (noninferiority margin, 0.3% percentage points). Secondary end points included change in fasting plasma glucose from baseline to week 26, mean weekly insulin dose during the last 2 weeks of treatment, body weight change from baseline to week 26, and number of level 2 (clinically significant; glucose level <54 mg/dL) and level 3 (severe; requiring external assistance for recovery) hypoglycemic episodes. RESULTS: Among 588 randomized participants (mean [SD] age, 58 [10] years; 219 [37%] women), 564 (96%) completed the trial. Mean HbA1c level decreased from 8.6% (observed) to 7.0% (estimated) at 26 weeks in the icodec group and from 8.5% (observed) to 7.2% (estimated) in the degludec group (estimated treatment difference [ETD], -0.2 [95% CI, -0.3 to -0.1] percentage points), confirming noninferiority (P < .001) and superiority (P = .002). There were no significant differences between the icodec and degludec groups for fasting plasma glucose change from baseline to week 26 (ETD, 0 [95% CI, -6 to 5] mg/dL; P = .90), mean weekly insulin dose during the last 2 weeks of treatment, or body weight change from baseline to week 26 (2.8 kg vs 2.3 kg; ETD, 0.46 [95% CI, -0.19 to 1.10] kg; P = .17). Combined level 2 or 3 hypoglycemia rates were numerically higher in the icodec group than the degludec group from week 0 to 31 (0.31 vs 0.15 events per patient-year exposure; P = .11) and statistically higher in the icodec group from week 0 to 26 (0.35 vs 0.12 events per patient-year exposure; P = .01). CONCLUSIONS AND RELEVANCE: Among people with insulin-naive type 2 diabetes, once-weekly icodec demonstrated superior HbA1c reduction to once-daily degludec after 26 weeks of treatment, with no difference in weight change and a higher rate of combined level 2 or 3 hypoglycemic events in the context of less than 1 event per patient-year exposure in both groups. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04795531.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lingvay I, Asong M, Desouza C, et al. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. JAMA. 2023. PMID: 37354562. doi:10.1001/jama.2023.11313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。